Hologic, Inc. HOLX announced an extension of its LOCalizer radiofrequency identification (“RFID”) tag’s CE Mark. Under the extended approval, the tag can now be implanted more than 30 days prior to ...
Rising incidence of breast cancer, growing adoption of breast-conserving surgeries, and increasing demand for minimally invasive and radiation-free localization technologies are the major factors ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) will reveal new technologies reimagining the future of breast health at the 110 th Scientific Assembly and Annual Meeting of the ...
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results